Authors
Loading...
Subtype-specific antithrombotic regimens were associated with differing mortality risks; leaves open whether randomized trials should test tailored secondary prevention.
Key points are not available for this paper at this time.
Kim et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: